VEGFR-2-IN-6

CAS No. 444731-47-9

VEGFR-2-IN-6( —— )

Catalog No. M34911 CAS No. 444731-47-9

VEGFR-2-IN-6 (WO 02/059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 250 In Stock
5MG 227 In Stock
10MG 353 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    VEGFR-2-IN-6
  • Note
    Research use only, not for human use.
  • Brief Description
    VEGFR-2-IN-6 (WO 02/059110, example 64) is a potent inhibitor of VEGFR2, a crucial receptor involved in the regulation of angiogenesis .
  • Description
    VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    444731-47-9
  • Formula Weight
    423.49
  • Molecular Formula
    C20H21N7O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 25 mg/mL (59.03 mM; Ultrasonic )
  • SMILES
    CN(c1ccc2c(C)n[nH]c2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Glaxo Wellcome House, et al. PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS. Patent WO 02/059110.
molnova catalog
related products
  • Cediranib

    A highly potent, orally bioavailable, pan-VEGFR inibitor with IC50 of 1, 5, 3 nM for VEGFR1, 2, 3, respectively.

  • TG 100801

    TG 100801 is a dual inhibitor of VEGFr2 and Src family (Src and YES) kinases and is a candidate compound for the treatment of age-related macular degeneration (AMD).

  • TAS-115

    TAS-115 is a potent inhibitor of VEGFR and hepatocyte growth factor receptor (c-Met/HGFR)-targeted kinase(IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively).